BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...and biosimilar manufacturers. The first U.S. biosimilar to make it to the U.S. market, Zarxio filgrastim-sndz...
...U.S., 11 biosimilars of seven innovator products have made it to market. Biosimilars of Neupogen filgrastim...
...competition for over four years, have gained over half of the total market share of filgrastim...
BioCentury | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

...of non-infringement in favor of the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) for Zarxio filgrastim-sndz...
BioCentury | Apr 19, 2019
Politics, Policy & Law

Thin U.S. biosimilars market fuels proposals to regulate biologics prices

...products, Neupogen filgrastim, as an example of the success of the U.S. biosimilars market. Zarxio filgrastim-sndz...
BioCentury | Mar 28, 2019
Product Development

Contracting practices limiting U.S. biosimilars uptake

...on the U.S. biosimilars market. Its Zarxio filgrastim-sndz, a biosimilar version of Amgen Inc.’s Neupogen filgrastim...
BioCentury | Nov 16, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...tests characterizing identity, purity and potency. Side-by-side comparisons of InSCyT-produced G-CSF vs. Amgen Inc.’s Neupogen filgrastim...
BioCentury | Nov 15, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...tests characterizing identity, purity and potency. Side-by-side comparisons of InSCyT-produced G-CSF vs. Amgen Inc.’s Neupogen filgrastim...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...or more per month Pfizer Inc. (NYSE:PFE) FDA approves Nivestym filgrastim-aafi, a biosimilar of Neupogen filgrastim...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Jul 27, 2018
Regulation

Biosimilar barriers

...they can enter the market. Pfizer Inc.’s Nivestym filgrastim-aafi, a biosimilar of Amgen Inc.’s Neupogen filgrastim...
...it is possible for a biosimilar to gain market share under the current circumstances. Zarxio filgrastim-sndz...
...was the first biosimilar that FDA approved, in March of 2015. Amgen’s neutropenia drug Neupogen filgrastim...
BioCentury | Jul 27, 2018
Clinical News

FDA approves Pfizer Nivestym, second Neupogen biosimilar

...FDA approved Nivestym filgrastim-aafi from Pfizer Inc. (NYSE:PFE), its biosimilar version of neutropenia drug Neupogen filgrastim...
...division of Novartis AG (NYSE:NVS; SIX:NOVN) markets the only other FDA-approved Neupogen biosimilar as Zarxio filgrastim-sndz...
...Nivestim - EU) filgrastim-aafi Business: Cancer, Hematology Allison Johnson GRAN, Granulokine, Grasin, Neupogen, filgrastim Nivestim, Nivestym, biosimilar filgrastim, filgrastim Amgen...
Items per page:
1 - 10 of 285